Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative
- 20 July 2021
- journal article
- research article
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 25 (4) , 677-683
Abstract
Background Decipher Biopsy is a commercially available gene expression classifier used in risk stratification of newly diagnosed prostate cancer (PCa). Currently, there are no prospective data evaluating its clinical utility. We seek to assess the clinical utility of Decipher Biopsy in localized PCa patients. Methods A multi-institutional study of 855 men who underwent Decipher Biopsy testing between February 2015 and October 2019. All patients were tracked through the prospective Michigan Urological Surgery Improvement Collaborative and linked to the Decipher Genomics Resource Information Database (GRID®; NCT02609269). Patient matching was performed by an independent third-party (ArborMetrix Inc.) using two or more unique identifiers. Cumulative incidence curves for time to treatment (TTT) and time to failure (TTF) were constructed using Kaplan–Meier estimates. Multivariable Cox proportional hazard models were used to evaluate the independent association of high-risk Decipher scores with the conversion from AS to radical therapy and treatment failure (biochemical failure or receipt of salvage therapy). Results and limitations Eight hundred fifty-five patients underwent Decipher Biopsy testing during the study period. Of the 855 men, 264 proceeded to AS (31%), and 454 (53%) received radical therapy. In men electing AS, after adjusting for NCCN risk group, age, PSA, prostate volume, body mass index, and percent positive cores, a high-risk Decipher score was independently associated with shorter TTT (HR 2.51, 95% CI 1.52–4.13 p < 0.001). Similarly, in patients that underwent radical therapy, a high-risk Decipher score was independently associated with TTF (HR 2.98, 95% CI 1.22–7.29, p = 0.01) on multivariable analysis. Follow-up time was a limitation. Conclusion In a prospective statewide registry, high-risk Decipher Biopsy score was strongly and independently associated with conversion from AS to definitive treatment and treatment failure. These real-world data support the clinical utility of Decipher Biopsy. An ongoing phase 3 randomized trial (NCT04396808) will provide level 1 evidence of the clinical impact of Decipher biopsy testing.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA240991-01)
This publication has 28 references indexed in Scilit:
- Prostate cancer risk stratification with magnetic resonance imagingUrologic Oncology: Seminars and Original Investigations, 2016
- Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis RiskUrology, 2016
- Combined Value of Validated Clinical and Genomic Risk Stratification Tools for Predicting Prostate Cancer Mortality in a High-risk Prostatectomy CohortEuropean Urology, 2015
- Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate CancerJournal of Clinical Oncology, 2015
- Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical ProstatectomyPLOS ONE, 2013
- Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS StudyEuropean Urology, 2013
- Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsiesBMC Genomics, 2013
- Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective studyThe Lancet Oncology, 2011
- Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of DiagnosisJNCI: Journal of the National Cancer Institute, 2009
- Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus ConferenceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006